Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › HROW

Harrow

HROW Rare disease Lead: Approved 2 Biotech Distilled articles ↓ 21 filings & releases ↓ Cash $83.9M (Jun 30, 2026) ↓ 2 verdicts ↓ 2 timing quotes ↓
Ophthalmology ProteinSmall Molecule

Market cap $1.01B 37.5M shares (10-Q, Aug 6, 2026) × $26.89 close Nov 6, 2026

Most recent annual filing: 2026-03-02

Catalyst timeline

12 trackedQuarter catalyst calendar →
  1. IHEEZO topline4Q 2026IHEEZO topline, 4Q 2026, material
  2. NATACYN topline4Q 2026NATACYN topline, 4Q 2026, material
  3. Harrow corporate updateNov 2026Harrow corporate update, Nov 2026, material
  4. TRIESENCE Ph3 toplineEarly 2027TRIESENCE Ph3 topline, Early 2027, material
  5. G-MELT NDA filing1H 2027G-MELT NDA filing, 1H 2027, notable
  6. OPUVIZ commercial launchJan 2027OPUVIZ commercial launch, Jan 2027, routine
  7. BYQLOVI corporate updateMar 4, 2027BYQLOVI corporate update, Mar 4, 2027, routine
  8. Harrow notes corporate updateMar 15, 2027Harrow notes corporate update, Mar 15, 2027, routine
  9. Novaliq non-compete divestiture clock corporate~Oct 2027Novaliq non-compete divestiture clock corporate, ~Oct 2027, routine
  10. G-MELT FDA approval1H 2028G-MELT FDA approval, 1H 2028, material
  11. TRIESENCE corporate update~Mar 31, 2028TRIESENCE corporate update, ~Mar 31, 2028, routine
  12. TYRVAYA corporate update~Apr–May 2028TYRVAYA corporate update, ~Apr–May 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (15 active programs)

MELT-400

  • Undisclosed indication

Technology platforms

Zydis ODT · Melt Pharmaceuticals

Oral dissolving tablet (ODT) drug delivery platform used as the delivery technology for Melt Pharmaceuticals' procedural sedation candidates including MELT-210, MELT-300, and MELT-400.

Capital (as filed)

Cash
$83.9M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
−$9.8M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$41.0M cash per the update of Oct 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Harrow, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-09-29 Watch Harrow, Inc. (HROW) — Scientific Deep Dive for VEVYE, IHEEZO, TRIESENCE, G-MELT and Pipeline Products VEVYE is a real share-taker but the stock assumes an H2 ramp the company has never delivered, on a balance sheet with minimal equity and high leverage, and the flagship licence as filed conflicts with keeping the TYRVAYA acquisition.
  2. 2026-10-06 Watch UPDATE: Harrow (HROW) - TYRVAYA Closes, Novaliq Still Missing TYRVAYA closing fixed the price and added Japan royalties but did not resolve the Novaliq non-compete conflict, and adds Q4 SG&A before TYRVAYA revenue arrives; the November Q3 print remains the key test.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (21)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)